- Home
- LII vs GMAB Comparison
LII vs GMAB Comparison
Compare LII & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LII
- GMAB
- Stock Information
- Founded
- LII 1895
- GMAB 1999
- Country
- LII United States
- GMAB Denmark
- Employees
- LII N/A
- GMAB N/A
- Industry
- LII Industrial Machinery/Components
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- LII Industrials
- GMAB Health Care
- Exchange
- LII Nasdaq
- GMAB Nasdaq
- Market Cap
- LII 20.6B
- GMAB 17.7B
- IPO Year
- LII 1999
- GMAB N/A
- Fundamental
- Price
- LII $554.86
- GMAB $27.52
- Analyst Decision
- LII Buy
- GMAB Buy
- Analyst Count
- LII 15
- GMAB 8
- Target Price
- LII $544.13
- GMAB $43.50
- AVG Volume (30 Days)
- LII 199.2K
- GMAB 429.5K
- Earning Date
- LII 10-24-2024
- GMAB 08-08-2024
- Dividend Yield
- LII 0.83%
- GMAB N/A
- EPS Growth
- LII 16.36
- GMAB 19.99
- EPS
- LII 18.03
- GMAB 12.13
- Revenue
- LII $5,019,400,000.00
- GMAB $2,732,097,558.00
- Revenue This Year
- LII $3.53
- GMAB $26.65
- Revenue Next Year
- LII $8.05
- GMAB $18.76
- P/E Ratio
- LII $30.75
- GMAB $22.08
- Revenue Growth
- LII 4.58
- GMAB 17.19
- 52 Week Low
- LII $334.53
- GMAB $24.53
- 52 Week High
- LII $594.65
- GMAB $38.80
- Technical
- Relative Strength Index (RSI)
- LII 44.68
- GMAB 51.87
- Support Level
- LII $542.08
- GMAB $27.38
- Resistance Level
- LII $591.29
- GMAB $27.93
- Average True Range (ATR)
- LII 14.35
- GMAB 0.36
- MACD
- LII -3.66
- GMAB 0.02
- Stochastic Oscillator
- LII 25.97
- GMAB 64.41
About LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.